XML 38 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation (Tables)
 3 Months Ended
Mar. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Schedule of Assumptions Used to Calculate Fair Value of Stock Options

 

Risk-free interest rates   2.72%
Expected term (in years)   2.6 
Volatility   95.0%
Grant date fair value of awards granted during the period  $1.13 
Summary of Stock Option Activity

A summary of Oncocyte’s 2018 Incentive Plan activity and related information follows (in thousands except weighted average exercise price):

 

   Shares   Number   Number   Weighted 
   Available   of Options   of RSUs   Average 
   for Grant   Outstanding   Outstanding   Exercise Price 
                 
Balance at December 31, 2022   8,832    8,560    441   $2.96 
RSUs vested   -    -    (214)  $- 
RSUs granted   -    -    -   $- 
Performance RSUs granted   -    -    -   $- 
Performance RSUs vested   -    -    -   $- 
Options granted   (2,779)   2,779    -   $0.44 
Options exercised   -    -    -   $- 
Options forfeited/cancelled   1,650    (1,650)   -   $- 
RSUs forfeited/cancelled   -    -    -   $- 
Balance at March 31, 2023   7,703    9,690    227   $2.14 
Options exercisable at March 31, 2023        3,969        $5.33 
Summary of Stock-based Compensation Expense

Oncocyte recorded stock-based compensation expense in the following categories on the accompanying condensed consolidated statements of operations for the three months ended March 31, 2023 and 2022 (unaudited and in thousands): 

 

   2023   2022 
   Three Months Ended 
   March 31, 
   2023   2022 
Cost of revenues  $10   $- 
Research and development   323    180 
Sales and marketing   77    33 
General and administrative   406    1,180 
Discontinuing operations   18    617 
Total stock-based compensation expense  $834   $2,010 
Schedule of Assumptions Used to Calculate Fair Value of Stock Options

The assumptions that were used to calculate the grant date fair value of Oncocyte’s employee and non-employee stock option grants for the three months ended March 31, 2023 and 2022 were as follows:

 

   Three Months Ended 
   March 31, 
   2023   2022 
Expected life (in years)   6.26    6.00 
Risk-free interest rates   3.72%   2.19%
Volatility   107.64%   107.03%
Dividend yield   -%   -%
Two Thousand Ten Plan Activity [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Summary of Stock Option Activity

A summary of Oncocyte’s 2010 Plan activity and related information follows (in thousands except weighted average exercise price):

 

   Shares   Number   Weighted 
   Available   of Options   Average 
Options  for Grant   Outstanding   Exercise Price 
             
Balance at December 31, 2022   -    607   $4.04 
Options exercised   -    -   $- 
Options forfeited, canceled and expired   -    -   $- 
Balance at March 31, 2023   -    607   $4.04 
Exercisable at March 31, 2023        607   $4.04